Creation of a lipoprotein(a) model to forecast progression-free survival and severe adverse events in metastatic lung adenocarcinoma patients lacking driver genes and with PD-L1 TPS under 50% - Takeaways - MDSpire

Creation of a lipoprotein(a) model to forecast progression-free survival and severe adverse events in metastatic lung adenocarcinoma patients lacking driver genes and with PD-L1 TPS under 50%

  • By

  • Sicong Li

  • Yiyuan Cui

  • Yijing Yan

  • Hao Li

  • Yue Jin

  • Yufan Chen

  • Jingjie Yu

  • Li Feng

  • April 24, 2026

  • 0 min

Share

  • 1

    The study focused on metastatic lung adenocarcinoma patients lacking driver genes and with PD-L1 TPS under 50% receiving first-line chemoimmunotherapy.

  • 2

    Serum lipoprotein(a) levels were found to independently predict progression-free survival in these patients undergoing treatment.

  • 3

    A total of 227 patients were followed, with the model achieving an AUC of 0.95 in the validation cohort for predicting 365-day progression-free survival.

  • 4

    AdaBoost was selected as the final model for predicting grade 3/4 adverse events due to its superior performance in accuracy and precision.

  • 5

    High serum LPA expression is identified as a risk factor, aiding in identifying patients less likely to benefit from initial chemoimmunotherapy.

Original Source(s)

Creation of a lipoprotein(a) model to forecast progression-free survival and severe adverse events in metastatic lung adenocarcinoma patients lacking driver genes and with PD-L1 TPS under 50%

  • by Sicong Li, Yiyuan Cui, Yijing Yan, Hao Li, Yue Jin, Yufan Chen, Jingjie Yu, Li Feng

  • April 24, 2026

Related Content

Can incorrect artificial intelligence (AI) results impact radiologists, and if so, what can we do about it? A multi-reader pilot study of lung cancer detection with chest radiography

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

Case Report: Nasal swelling and ulceration as a unique immune-related cutaneous adverse event of atezolizumab in small cell lung cancer